![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: IL1R1 |
Gene summary for IL1R1 |
![]() |
Gene information | Species | Human | Gene symbol | IL1R1 | Gene ID | 3554 |
Gene name | interleukin 1 receptor type 1 | |
Gene Alias | CD121A | |
Cytomap | 2q11.2-q12.1 | |
Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | P14778 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3554 | IL1R1 | Dong_P1 | Human | Prostate | Tumor | 1.83e-19 | 6.26e-02 | 0.035 |
3554 | IL1R1 | Dong_P3 | Human | Prostate | Tumor | 5.47e-06 | 2.95e-02 | 0.0278 |
3554 | IL1R1 | Dong_P4 | Human | Prostate | Tumor | 1.25e-06 | 1.60e-01 | 0.0292 |
3554 | IL1R1 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 2.06e-04 | 5.16e-01 | 0.1621 |
3554 | IL1R1 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 9.91e-03 | 4.44e-01 | 0.1602 |
3554 | IL1R1 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 3.91e-03 | 3.96e-01 | 0.1569 |
3554 | IL1R1 | male-WTA | Human | Thyroid | PTC | 1.12e-18 | -6.58e-03 | 0.1037 |
3554 | IL1R1 | PTC01 | Human | Thyroid | PTC | 3.52e-03 | -4.37e-02 | 0.1899 |
3554 | IL1R1 | PTC04 | Human | Thyroid | PTC | 2.18e-05 | 6.90e-02 | 0.1927 |
3554 | IL1R1 | PTC05 | Human | Thyroid | PTC | 1.20e-04 | 4.75e-01 | 0.2065 |
3554 | IL1R1 | PTC06 | Human | Thyroid | PTC | 2.65e-11 | 4.48e-01 | 0.2057 |
3554 | IL1R1 | PTC07 | Human | Thyroid | PTC | 1.53e-16 | 2.90e-01 | 0.2044 |
3554 | IL1R1 | ATC09 | Human | Thyroid | ATC | 4.20e-04 | -4.14e-02 | 0.2871 |
3554 | IL1R1 | ATC11 | Human | Thyroid | ATC | 5.81e-03 | 9.10e-02 | 0.3386 |
3554 | IL1R1 | ATC12 | Human | Thyroid | ATC | 1.50e-03 | -1.11e-01 | 0.34 |
3554 | IL1R1 | ATC13 | Human | Thyroid | ATC | 8.13e-08 | -2.38e-02 | 0.34 |
3554 | IL1R1 | ATC1 | Human | Thyroid | ATC | 6.01e-03 | -4.71e-02 | 0.2878 |
3554 | IL1R1 | ATC2 | Human | Thyroid | ATC | 4.84e-10 | 1.57e+00 | 0.34 |
3554 | IL1R1 | ATC5 | Human | Thyroid | ATC | 5.22e-07 | -5.64e-03 | 0.34 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00975298 | Cervix | CC | myeloid leukocyte migration | 56/2311 | 220/18723 | 7.21e-08 | 4.15e-06 | 56 |
GO:00018197 | Cervix | CC | positive regulation of cytokine production | 95/2311 | 467/18723 | 4.88e-07 | 1.85e-05 | 95 |
GO:00509007 | Cervix | CC | leukocyte migration | 78/2311 | 369/18723 | 1.09e-06 | 3.80e-05 | 78 |
GO:00975308 | Cervix | CC | granulocyte migration | 39/2311 | 148/18723 | 2.67e-06 | 7.87e-05 | 39 |
GO:00026857 | Cervix | CC | regulation of leukocyte migration | 50/2311 | 210/18723 | 2.95e-06 | 8.31e-05 | 50 |
GO:00026878 | Cervix | CC | positive regulation of leukocyte migration | 35/2311 | 135/18723 | 1.25e-05 | 2.60e-04 | 35 |
GO:19902666 | Cervix | CC | neutrophil migration | 32/2311 | 122/18723 | 2.25e-05 | 4.00e-04 | 32 |
GO:00507273 | Cervix | CC | regulation of inflammatory response | 75/2311 | 386/18723 | 3.95e-05 | 6.18e-04 | 75 |
GO:19026244 | Cervix | CC | positive regulation of neutrophil migration | 11/2311 | 28/18723 | 2.84e-04 | 3.07e-03 | 11 |
GO:00192213 | Cervix | CC | cytokine-mediated signaling pathway | 84/2311 | 472/18723 | 3.25e-04 | 3.44e-03 | 84 |
GO:00024564 | Cervix | CC | T cell mediated immunity | 26/2311 | 109/18723 | 6.39e-04 | 5.97e-03 | 26 |
GO:00027118 | Cervix | CC | positive regulation of T cell mediated immunity | 16/2311 | 56/18723 | 8.97e-04 | 7.74e-03 | 16 |
GO:00026973 | Cervix | CC | regulation of immune effector process | 62/2311 | 339/18723 | 9.25e-04 | 7.84e-03 | 62 |
GO:00027201 | Cervix | CC | positive regulation of cytokine production involved in immune response | 17/2311 | 65/18723 | 1.84e-03 | 1.37e-02 | 17 |
GO:00027095 | Cervix | CC | regulation of T cell mediated immunity | 20/2311 | 85/18723 | 3.04e-03 | 2.00e-02 | 20 |
GO:00024603 | Cervix | CC | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 62/2311 | 356/18723 | 3.09e-03 | 2.03e-02 | 62 |
GO:0002443 | Cervix | CC | leukocyte mediated immunity | 73/2311 | 440/18723 | 5.01e-03 | 2.98e-02 | 73 |
GO:0002699 | Cervix | CC | positive regulation of immune effector process | 43/2311 | 235/18723 | 5.13e-03 | 3.02e-02 | 43 |
GO:0002819 | Cervix | CC | regulation of adaptive immune response | 35/2311 | 183/18723 | 5.38e-03 | 3.11e-02 | 35 |
GO:00019612 | Cervix | CC | positive regulation of cytokine-mediated signaling pathway | 13/2311 | 50/18723 | 6.42e-03 | 3.58e-02 | 13 |
Page: 1 2 3 4 5 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541820 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0513020 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0513120 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
hsa0516620 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
hsa051465 | Cervix | CC | Amoebiasis | 29/1267 | 102/8465 | 3.31e-04 | 1.70e-03 | 1.01e-03 | 29 |
hsa046596 | Cervix | CC | Th17 cell differentiation | 28/1267 | 108/8465 | 1.99e-03 | 7.98e-03 | 4.72e-03 | 28 |
hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa05418110 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa05130110 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa0516319 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa05131110 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
hsa05166110 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
hsa0514612 | Cervix | CC | Amoebiasis | 29/1267 | 102/8465 | 3.31e-04 | 1.70e-03 | 1.01e-03 | 29 |
hsa0465911 | Cervix | CC | Th17 cell differentiation | 28/1267 | 108/8465 | 1.99e-03 | 7.98e-03 | 4.72e-03 | 28 |
hsa0401012 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa0513044 | Cervix | N_HPV | Pathogenic Escherichia coli infection | 25/349 | 197/8465 | 4.71e-07 | 8.00e-06 | 6.25e-06 | 25 |
hsa0541845 | Cervix | N_HPV | Fluid shear stress and atherosclerosis | 20/349 | 139/8465 | 9.29e-07 | 1.41e-05 | 1.10e-05 | 20 |
hsa0516643 | Cervix | N_HPV | Human T-cell leukemia virus 1 infection | 22/349 | 222/8465 | 1.17e-04 | 1.18e-03 | 9.23e-04 | 22 |
hsa0465941 | Cervix | N_HPV | Th17 cell differentiation | 14/349 | 108/8465 | 1.30e-04 | 1.22e-03 | 9.57e-04 | 14 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
IL1B | IL1R1_IL1RAP | IL1B_IL1R1_IL1RAP | IL1 | Breast | DCIS |
IL1A | IL1R1_IL1RAP | IL1A_IL1R1_IL1RAP | IL1 | Cervix | CC |
IL1B | IL1R1_IL1RAP | IL1B_IL1R1_IL1RAP | IL1 | Cervix | CC |
IL1A | IL1R1_IL1RAP | IL1A_IL1R1_IL1RAP | IL1 | HNSCC | Precancer |
IL1B | IL1R1_IL1RAP | IL1B_IL1R1_IL1RAP | IL1 | HNSCC | Precancer |
IL1B | IL1R1_IL1RAP | IL1B_IL1R1_IL1RAP | IL1 | Liver | Healthy |
IL1B | IL1R1_IL1RAP | IL1B_IL1R1_IL1RAP | IL1 | Liver | Precancer |
IL1B | IL1R1_IL1RAP | IL1B_IL1R1_IL1RAP | IL1 | Lung | AIS |
IL1A | IL1R1_IL1RAP | IL1A_IL1R1_IL1RAP | IL1 | Lung | IAC |
IL1B | IL1R1_IL1RAP | IL1B_IL1R1_IL1RAP | IL1 | Lung | IAC |
IL1A | IL1R1_IL1RAP | IL1A_IL1R1_IL1RAP | IL1 | Lung | MIAC |
IL1B | IL1R1_IL1RAP | IL1B_IL1R1_IL1RAP | IL1 | Lung | MIAC |
IL1B | IL1R1_IL1RAP | IL1B_IL1R1_IL1RAP | IL1 | Lung | Precancer |
IL1B | IL1R1_IL1RAP | IL1B_IL1R1_IL1RAP | IL1 | Skin | ADJ |
IL1B | IL1R1_IL1RAP | IL1B_IL1R1_IL1RAP | IL1 | Skin | AK |
IL1B | IL1R1_IL1RAP | IL1B_IL1R1_IL1RAP | IL1 | Skin | SCCIS |
IL1B | IL1R1_IL1RAP | IL1B_IL1R1_IL1RAP | IL1 | THCA | Cancer |
IL1B | IL1R1_IL1RAP | IL1B_IL1R1_IL1RAP | IL1 | THCA | PTC |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IL1R1 | SNV | Missense_Mutation | c.231N>G | p.His77Gln | p.H77Q | P14778 | protein_coding | tolerated(0.94) | benign(0.011) | TCGA-AO-A0J3-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD | |
IL1R1 | SNV | Missense_Mutation | rs746389545 | c.1657N>C | p.Ser553Pro | p.S553P | P14778 | protein_coding | tolerated(0.2) | benign(0.006) | TCGA-B6-A1KN-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
IL1R1 | SNV | Missense_Mutation | c.1135N>C | p.Ala379Pro | p.A379P | P14778 | protein_coding | deleterious(0.03) | benign(0.022) | TCGA-D8-A1XW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD | |
IL1R1 | SNV | Missense_Mutation | c.1354N>C | p.Ile452Leu | p.I452L | P14778 | protein_coding | deleterious(0.02) | benign(0.393) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
IL1R1 | SNV | Missense_Mutation | c.989N>A | p.Pro330Gln | p.P330Q | P14778 | protein_coding | deleterious(0.02) | probably_damaging(0.95) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
IL1R1 | SNV | Missense_Mutation | rs772263623 | c.1696G>A | p.Val566Met | p.V566M | P14778 | protein_coding | tolerated_low_confidence(0.12) | benign(0.003) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
IL1R1 | SNV | Missense_Mutation | c.847N>G | p.Asn283Asp | p.N283D | P14778 | protein_coding | tolerated(0.44) | benign(0.013) | TCGA-AA-3956-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
IL1R1 | SNV | Missense_Mutation | c.237G>T | p.Glu79Asp | p.E79D | P14778 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
IL1R1 | SNV | Missense_Mutation | c.1002C>A | p.Phe334Leu | p.F334L | P14778 | protein_coding | tolerated(0.12) | benign(0.015) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
IL1R1 | SNV | Missense_Mutation | rs56337419 | c.76N>T | p.Arg26Cys | p.R26C | P14778 | protein_coding | tolerated(0.19) | benign(0.014) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3554 | IL1R1 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | antagonist | CHEMBL1201570 | ANAKINRA | |
3554 | IL1R1 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | Anakinra | ANAKINRA | ||
3554 | IL1R1 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | IL-1 | 8844493,9923819,2162889 | ||
3554 | IL1R1 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | IL-1RA | ANAKINRA | 9555664 | |
3554 | IL1R1 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | IL-1 | |||
3554 | IL1R1 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | GENISTEIN | GENISTEIN | 10400830 | |
3554 | IL1R1 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | ETHANOL | ALCOHOL | 16272348 | |
3554 | IL1R1 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | EPO | EPOETIN ALFA | 16337691 | |
3554 | IL1R1 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | RETINOIC ACID | 2465548 | ||
3554 | IL1R1 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | VITAMIN D | 12193704 |
Page: 1 2 |